Eisai, Arena release BELVIQ XR weight-loss drug
Eisai Inc. and Arena Pharmaceuticals have released BELVIQ XR, a medication designed to help individuals lose weight and maintain their weight loss. Read More »
TRACON completes meetings with FDA, EMA for Phase 3 TRC-105 trial
TRACON Pharmaceuticals has completed its “End-of-Phase 2” meeting with the U.S. Food and Drug Administration and its “Protocol Assistance Meeting” with the European Medicines Agency. Read More »
Aralez launches YOSPRALA in U.S.
Aralez Pharmaceuticals' YOSPRALA -- a once-a-day medication that combines aspirin, an anti-platelet agent and omeprazole into a proton pump inhibitor (PPI) -- is now available in the United States. Read More »
CVS Health launches October celebration for American Pharmacists Month
CVS Health has launched an October celebration to recognize the approximately 30,000 pharmacists employed in CVS Pharmacies who help people obtain better health as part of American Pharmacists Month. Read More »
Genentech's Alecensa granted Breakthrough Therapy Designation
Genentech's anaplastic lymphoma kinase inhibitor Alecensa has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Read More »
CVS Health CEO to speak about health care in Chicago
CVS Health President and CEO Larry Merlo will speak at an Executive Club of Chicago event to discuss how health care in the Untied States is accessed, delivered and financed. Read More »
Walgreens to honor 27,000 team members for American Pharmacists Month
Walgreens will recognize approximately 27,000 pharmacists serving communities across the country in celebration of American Pharmacists Month. Read More »
Aralez Pharmaceuticals to acquire U.S. rights to Toprol-XL
Aralez Pharmaceuticals has reached an agreement to acquire the rights to Toprol-XL in the United States as well as its Authorized Generic from AstraZeneca. Read More »
Anavex enters collaborative agreement with Ariana Pharma
Anavex Life Sciences Corp. has entered into a collaborative agreement with Ariana Pharma to allow Anavex to use Ariana's proprietary Knowledge, Extraction, Management stratification technology to expedite the clinical development timelines of its ANAVEX 2-73 Phase 2/3 trial. Read More »
CymaBay determines next step in MBX-8025 process
CymaBay Therapeutics has determined the next course for the development of MBX-8025 in patients with primary biliary cholangitis after the U.S. Food and Drug Administration gave the company input on the process. Read More »
Eli Lilly to present data at European Society of Medical Oncology Congress
Eli Lilly and Co. will present data at the European Society of Medical Oncology’s 2016 Congress in Copenhagen from a number of clinical studies that will serve to further strengthen the development of its diverse clinical cancer portfolio. Read More »
Preferred pharmacy plans rally in comeback
Recent data from the Baltimore, Maryland-based Centers for Medicare & Medicaid Services (CMS) suggests that over eight out of ten Medicare Part D regional prescription drug plans (PDP) will utilize preferred network plans in 2017. Read More »
Catabasis Pharmaceuticals adds to two leadership team
Catabasis Pharmaceuticals' Andrew Nichols has been named the company’s new chief scientific officer and Angelika Fretzen has been named senior vice president of product development. Read More »
Walgreens reminds customers about prescription preparedness
In the wake of Hurricane Matthew bearing down on the East Coast, Walgreens is reminding its pharmacy patients about how important prescription preparedness is in times like these. Read More »
CVS Health makes preparations for patients when hurricanes loom
In the wake of Hurricane Matthew, CVS Health reminds its customers to properly prepare their prescriptions and take care of their needs when storms are approaching their areas. Read More »
ZUMA-6 clinical trial enrolls first patient
Kite Pharma has enrolled its first patient into the Phase 1b/2 ZUMA-6 clinical trial involving KTE-C19. Read More »
FDA approves two new dosing options for ZUBSOLV
.jpg)
The buprenorphine/naloxone CIII sublingual tablet ZUBSOLV from Orexo US has been approved by the U.S. Food and Drug Administration. Read More »
Allergan, DMRF continue collaboration to bring awareness to dystonia
Allergan will continue its collaborative efforts with Dystonia Medical Research Foundation to support patients with dystonia by conducting a survey that will assess cervical dystonia awareness, its symptoms and options for treatment that will inspire education and the correct diagnosis of the condition, which can often be disabling. Read More »
FDA accepts Coherus’ BLA for CHS-1701
Coherus BioSciences has filed of its 351(k) Biologics License Application for its pegfilgrastim biosimilar candidate CHS-1701 has been accepted by the U.S. Food and Drug Administration. Read More »
CVS Health awards WomenHeart community grant
WomenHeart: The National Coalition for Women with Heart Disease has received a community grant from CVS Health to help build healthier communities and support nonprofit organizations assisting underserved populations receive health care. Read More »
Alerts Sign-up